Bushen-Qingxin decoction combined conjugated estrogen tablets for perimenopausal women osteoporosis in patients with bone mineral density and bone metabolic markers / 国际中医中药杂志

Objective Bushen-Qingxin decoction combined conjugated estrogen tablets of modulation perimenopausal women osteoporosis patients, explore the impact of bone mineral density and bone metabolic markers. Methods A total of 160 female patients were recruited in our hospital by the random number table method, and were divided into the control group 80 cases and the observation group 80 cases. The control group was treated with standard dose of conjugated estrogen tablets, while the observation group was treated with Bushen Qingxin decoction on the basis of the control group. Both groups were treated 3 period with 28 days per period. The enzyme-linked immunity analyzer was used to detect serum bone-specific alkaline phosphatase (BALP), C-terminal cross linked peptide (CTX-Ⅰ), tartrate resistant acid phosphatase -5b (TRACP-5b) level, and the dual-energy X-ray absorptiometry measurement method was used to detect bone mineral density values. The clinical curative effect was compared between two groups. Results The total effective rate of the observation group was 91.3%, while the control group was 78.8%, which showed the difference was statistically significant (χ 2=3.971, P=3.971). After treatment, the serum BALP levels (88.55 ± 10.33 U/L vs. 80.47 ± 8.67 U/L, t=5.399) of the observation group were significantly higher than this of the control group (P<0.01). After treatment, the serum TRACP-5b (501.31 ± 35.77 pg/L vs. 538.51 ± 37.69 pg/L, t=6.498), CTX- (130.09 ±Ⅰ17.55 ng/ml vs. 164.71 ± 19.45 ng/ml, t=11.928) of the observation group were significantly lower than those of the control group (P<0.01). After treatment, the bone mineral density of the observation group rose up from the baseline (t=3.396, P=0.010). Conclusions The Bushen-Qingxin decoction combined conjugated estrogen tablets can increase on women in the menopausal transition of osteoporosis in patients with bone mineral density values and serum BALP levels, reduce serum TRACP-5b, CTX-Ⅰ level.

Impact of patient background factors on the treatment efficacy of once-weekly teriparatide

OBJECTIVES: The impact of patient background factors on changes in bone mineral density (BMD) and bone metabolic markers after treatment with once-weekly teriparatide (W-TPTD) has not been fully elucidated. To clarify the impact, I performed stratified analysis in addition to the efficacy and safety assessments to analyze treatment data with W-TPTD. METHODS: The primary endpoint of the efficacy was the rate of change of the lumbar spine BMD at 18 months after treatment. In the exploratory analysis, bone metabolic markers at baseline were used to divide the patients into 3 groups, by the first tertile and the second tertile. The rate of change in the lumbar spine/femoral neck BMD and bone metabolic markers in each group were analyzed by stratification. RESULTS: The rate of change in the lumbar spine BMD at 18 months was 9.0%, which represented a significant increase. The rate of change in the lumbar spine/femoral neck BMD in each group classified into tertiles by their baseline bone metabolic markers significantly increased, regardless of the type of bone metabolic markers and baseline value. For markers, all groups remained within the range of reference values at 18 months after treatment. CONCLUSIONS: I demonstrated that W-TPTD significantly increased the BMD of the lumbar spine and femur, regardless of baseline values of the bone metabolic markers. In addition, W-TPTD was able to normalize bone metabolic markers. I considered that W-TPTD would be useful, independent of bone metabolic markers in patients, as an agent to improve BMD, and be a useful option for the treatment of osteoporosis.

Bone Metabolic Markers in Patients with Obstructive Sleep Apnea Syndrome / 中华医学杂志(英文版)

Background@#Obstructive sleep apnea syndrome (OSAS) is prevalent in obesity and is associated with many metabolic abnormalities. The relationship between OSAS and bone metabolism is still unclear. The aim of this study was to investigate the relationship between the severity of OSAS and bone metabolic markers.@*Methods@#A total of 119 obese males were enrolled in this study in spring months from 2015 to 2017. All candidates underwent polysomnography, and their bone mineral density (BMD) and the serum levels of total procollagen type 1 N-terminal propeptide (t-P1NP), N-terminal midfragment of osteocalcin (N-MID), β-C-terminal telopeptide of type 1 collagen (β-CTX), vitamin D (VD), and parathyroid hormone (PTH) were measured. The analysis of variance and Pearson correlation analysis were performed for data analyses.@*Results@#No significant differences in the mean values of BMD were observed among the obesity, mild-to-moderate OSAS, and severe OSAS groups; and the serum levels of t-P1NP and β-CTX in the severe OSAS group were significantly higher than those in the obesity group (48.42 ± 23.78 ng/ml vs. 31.98 ± 9.85 ng/ml, P < 0.001; 0.53 ± 0.24 ng/ml vs. 0.41 ± 0.13 ng/ml, P = 0.011, respectively). The serum level of VD in the obesity group was significantly higher than those in the mild-to-moderate and severe OSAS groups (both P < 0.001), and decreased as the severity of OSAS increased (P < 0.001). The serum level of PTH in the severe OSAS group was significantly higher than those in the obesity and mild-to-moderate OSAS groups (both P < 0.001). The results of correlation analysis indicated that the level of apnea-hypopnea index (AHI) was correlated with the levels of t-P1NP (r = 0.396, P < 0.001), VD (r = -0.404, P < 0.001), and PTH (r = 0.400, P < 0.001), whereas the level of minimum Osaturation (SaOmin) was correlated with the levels of VD (r = 0.258, P = 0.016) and PTH (r = -0.376, P < 0.001).@*Conclusions@#The levels of bone resorption and formation markers in patients with severe OSAS were significantly increased compared to obese men, and the severity of OSAS was correlated with the serum levels of t-P1NP, VD, and PTH.

Relationship between Bone Mineral Density and Bone Metabolic Biochemical Markers and Diet Quality Index-International(DQI-I) in Postmenopausal Obese Women / 대한지역사회영양학회지

OBJECTIVES: This study compared the differences of postmenopausal women's bone mineral density in relation to the degree of obesity, metabolism index and dietary factors that affect bone mineral density. METHODS: The subjects included in the study are 39 postmenopausal women of normal weight with body mass index less than 25 kg/m2 and 32 postmenopausal who are obese. Anthropometry and biochemical analysis were performed and nutrient intakes and DQI-I were assessed. RESULTS: Normal weight women were 56.03 ± 3.76 years old and obese women were 58.09 ± 5.13 years old and there was no significant difference in age between the two groups. The T-score of bone mineral density was 0.03 ± 1.06 in normal weight women and -0.60 ± 1.47 in obese women and this was significantly different between the two groups (p<0.05). Blood Leptin concentration was significantly lower in normal weight women (6.09 ± 3.37 ng/mL) compared to obese women in (9.01 ± 4.99 ng/mL) (p<0.05). The total score of diet quality index-international was 70.41±9.34 in normal weight women and 64.93 ± 7.82 in obese women (p<0.05). T-score of bone mineral density showed negative correlations with percentage of body fat (r = -0.233, p=0.05), BMI (r = -0.197, p=0.017), triglyceride (r = -0.281, p=0.020) and leptin (r = -0.308, p=0.011). The results of multiple regression analysis performed as the method of entry showed that with 22.0% of explanation power, percentage of body fat (β=-0.048, p<0.05), triglyceride (β=-0.005, p<0.05) and HDL-cholesterol (β=0.034, p<0.01), moderation of DQI-I (β=-0.231, p<0.05) affected T-score significantly. CONCLUSIONS: The results of the study showed that obese women have less bone density than those with normal weight women. In addition, the factor analysis result that affect bone mineral density showed that intake of fat is a very important factor. Therefore, postmenopausal women need to maintain normal weight and manage blood lipid levels within normal range. They also need to take various sources of protein and reduce consumption of empty calorie foods that have high calories, fat, cholesterol and sodium.

Correlation of serum uric acid with bone mineral density and bone metabolic markers in middle-aged Chinese physical examination population / 第二军医大学学报

Objective To investigate the correlation of uric acid (UA) levels with bone mineral density (BMD) and serum bone metabolic markers in middle-aged Chinese physical examination population, so as to discuss the possible role of UA in bone metabolism. Methods A cross-sectional study with 214 middle-aged (45 to 65 years) Chinese physical examination participants was carried out. The correlation of UA levels with BMD and serum bone metabolic markers was observed. BMD values of the lumbar spine, total hip, femur neck and the whole body were measured by dual energy X-ray method. Bone turnover markers, including bone formation markers osteocalcin (OC) and procollagen type amino-terminal propeptide (PNP), bone resorption marker β-CrossLaps (β-CTX), 25-hydroxyvitamin D3 (25-OHD3), and parathyroid hormone (PTH) were measured by ECL immunoassay. Results After adjusting for multiple confounders, serum UA levels were found positively correlated with BMD at the lumbar spine, total hip and whole body (P≤0.001), negatively correlated with OC (P<0.01), and positively correlated with logPTH and log25-OHD3 (P=0.039, P=0.032). The participants were divided into high UA group (UA≥60 mg/mL) and low UA group (UA<60 mg/L) according to the serum UA level. OC, PNP and β-CTX were found significantly lower in the high UA group than in the low UA group (P<0.01). Then we divided the participants into three groups (T1: UA #x003C;47 mg/L,T2: 47 mg/L≤UA <60 mg/L; T3: UA≥60 mg/L) according to the serum UA level, and we found that the odds for osteoporosis and at least osteopenia increased by 41% and 158% in T1 group compared with in T3 group, respectively. Conclusion UA plays a protective role in bone metabolism of middle-aged Chinese population, and the relative comclusions need to be confirmed by further studies.

Study on application of determination of bone metabolic biochemical indexes in early diagnosis of middle and old age osteoporosis / 国际检验医学杂志

Objective To investigate the application value of determining the levels of biochemical indexes of bone metabolism in the early diagnosis of middle and old age osteoporosis.Methods 241 middle and old aged individuals undergoing the physical exami-nation in the health management center of our hospital from October 2012 to October 2013 were selected,determined the bone min-eral density(BMD)of the lumbar spine and divided into the normal bone mass group(n=66),osteopenia group(n=58),osteoporosis group(n= 63 )and severe osteoporosis group(n =54)according to the different BMD.The serum levels of bone-specific alkaline phosphatase(B-ALP),insulin-like growth factor-1(IGF-1)and tartrate-resistant acid phosphatase 5b(TRACP5b)were detected.The detection values of biochemical markers of bone metabolism in the four groups were statistically analyzed.Results There were sta-tistically significant differences in the serum levels of TRACP5b,B-ALP and IGF-1 among the four groups(P <0.05).The serum levels of TRACP5b,B-ALP and IGF-1 also had statistically significant differences between the osteopenia group,osteoporosis group and severe osteoporosis group with the normal bone mass group too(P <0.05);the serum levels of TRACP5b and B-ALP were in-creased with the decrease of bone mass(P <0.05),while the serum level of IGF-1 was decreased with the decrease of bone mass(P<0.05).Conclusion Detecting the serum levels of TRACP5b,B-ALP and IGF-1 is conducive to the early diagnosis of middle and old age primary osteoporosis.